Omeros Message Board - Msg: 31486277

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Omeros

OMER 7.330

-2.5%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Julius Wong	2/15/2018 8:19:15 AM
	of 464

Omeros gets panned Finally, shares of Omeros plunged nearly 18%. The small biotechnology company was the subject of a negative report from short-side research specialist FourWorld Capital Management, which set a $4 per share price on the stock. Followers of the company are concerned that the federal government didn't explicitly extend favorable Medicare reimbursement provisions for its cataract surgery product Omidria, and the move could threaten to hurt revenue going forward. After nearly doubling in 2017, Omeros' stock will need Omidria to be a hit in order to sustain recent gains. finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next